Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Vivosim Labs Inc's Business Segments
Vivosim Labs Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Royalty
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Royalty100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 0 | 100% |
Annual Results
Revenue Share by Reportable Segment - FY
- Royalty100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 0 | 100% |
Revenue by Product & Service Category - FY
- Royalty100%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Royalty | $ 0 | 100% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Vivosim Labs Inc
The company operates in the pharmaceutical and biotechnology industry, focusing on a services platform and drug discovery business. Its success depends on attracting and retaining qualified scientific, clinical, and executive personnel amid intense competition. The company currently lacks committed external funding and does not anticipate meaningful revenue in the near term. It plans to finance operations through equity offerings, debt financings, government or third-party funding, and licensing or collaboration arrangements, which may dilute existing stockholders' interests. The company has an effective shelf registration statement and an agreement with JonesTrading Institutional Services LLC to sell common stock through an "at the market offering," having raised approximately $52.0 million as of March 31, 2026, subject to limitations based on its public float. The company supports external clinical development by third parties and pursues its own research and development programs. Drug candidates require extensive and costly clinical trials and regulatory approvals before marketing, with uncertain timelines and outcomes. The company may complete trials internally or partner with pharmaceutical companies. Failure to complete development or obtain approvals could increase costs and hinder revenue generation. Risks such as trial delays, enrollment issues, negative results, or regulatory suspensions may affect the company's ability to commercialize drug candidates and achieve financial milestones.
As of March 31, 2026, the Company operated a single segment. The Company previously had a product-based division called Mosaic, established in the fourth quarter of fiscal 2024, which produced cell-based products for research and development and life science customers. Mosaic's commercial operations ceased in the third quarter of fiscal 2025.